Research Excellence Award
Pere Domingo
Hospital de la Santa Creu i Sant Pau, Spain
| Pere Domingo |
| Affiliation |
Hospital de la Santa Creu i Sant Pau |
| Country |
Spain |
| Scopus ID |
7102960369 |
| Documents |
738 |
| Citations |
24,147 |
| h-index |
70 |
| Subject Area |
Infectious Diseases |
| Event |
Business Global Awards |
| ORCID |
0000-0003-1138-5770 |
Pere Domingo is a researcher in infectious diseases affiliated with Hospital de la Santa Creu i Sant Pau in Spain. His scholarly profile comprises 738 documents, 24,147 citations, and an h-index of 70, indicating a substantial body of indexed research and sustained scholarly visibility. His recent work includes studies addressing cardiovascular prevention in people with HIV, antiretroviral therapy, gut microbiota, hepatitis C epidemiology, and emerging HIV treatment strategies.
Abstract
Pere Domingo’s research profile reflects sustained engagement with contemporary infectious-disease questions, particularly HIV medicine and related comorbidities. Recent publications examine precision cardiovascular prevention following REPRIEVE, emerging integrase strand transfer inhibitors, antiretroviral effects on gut microbiota, and hepatitis C trends among people with HIV in Spain. [1] [2]
Keywords
Infectious Diseases; HIV; Antiretroviral Therapy; Cardiovascular Prevention; Gut Microbiota; Hepatitis C; Precision Medicine; Clinical Research.
Introduction
Contemporary HIV research increasingly considers long-term health outcomes beyond viral suppression, including cardiovascular risk, immune recovery, metabolic effects, and coinfections. Domingo’s recent publication record addresses several of these interconnected areas, placing clinical infectious-disease research within a broader framework of prevention and patient-centered care. [1] [4]
Research Profile
The available bibliometric profile records 738 documents, 24,147 citations, and an h-index of 70 under Scopus author ID 7102960369. These indicators provide a quantitative description of publication activity and citation reach, while individual studies provide additional evidence of the researcher’s involvement in clinically relevant infectious-disease investigations.
Research Contributions
- Evaluation of cardiovascular prevention strategies for people living with HIV after the REPRIEVE trial.
- Investigation of emerging antiretroviral therapies and resistance profiles in HIV treatment. [2]
- Clinical investigation of antiretroviral effects on gut microbiota. [3]
- Longitudinal assessment of hepatitis C prevalence among people with HIV in Spain. [4]
Publications
Recent publications include Beyond Lipid Lowering: A Narrative Review and Expert Perspective on Precision Cardiovascular Prevention in People with HIV After REPRIEVE, published in Biomolecules on 29 August 2026; Proof-of-Concept Phase 2a Trial of VH4524184 in Clinical Infectious Diseases; and research on dolutegravir, gut microbiota, and hepatitis C epidemiology. [1] [2] [3] [4]
Research Impact
The combination of a substantial indexed publication record and 24,147 citations indicates considerable bibliometric visibility. The thematic range of recent work also demonstrates relevance to prevention, treatment innovation, microbiome research, and infectious-disease epidemiology. Such areas have direct implications for understanding and improving long-term outcomes in people affected by HIV.
Award Suitability
The Research Excellence Award recognizes scholarly achievement supported by research productivity, measurable academic impact, and relevance to an established field. Domingo’s recorded Scopus metrics, specialization in infectious diseases, and recent peer-reviewed publications collectively provide a documented basis for consideration within an academic recognition framework.
Conclusion
Pere Domingo’s research profile reflects sustained scholarly activity in infectious diseases, with particular relevance to HIV treatment, prevention, coinfections, and long-term clinical outcomes. His bibliometric record and recent publications support recognition of a significant contribution to contemporary infectious-disease research.
External Links
References
- Domingo, P. et al. (2026). Beyond Lipid Lowering: A Narrative Review and Expert Perspective on Precision Cardiovascular Prevention in People with HIV After REPRIEVE. Biomolecules, 16(9), 1254.
https://doi.org/10.3390/biom16091254
- Domingo, P. et al. (2026). Proof-of-Concept Phase 2a Trial of VH4524184: An Emerging Third-Generation Integrase Strand Transfer Inhibitor With an Enhanced Resistance Profile. Clinical Infectious Diseases.
https://doi.org/10.1093/cid/ciag357
- Domingo, P. et al. (2026). Dolutegravir restores gut microbiota in late-stage HIV-1 unlike darunavir: an open-label, randomized clinical trial. Nature Communications.
https://doi.org/10.1038/s41467-026-69846-7
- Domingo, P. et al. (2026). Trends in Hepatitis C Virus Infection Prevalence Among People With HIV in Spain Over 2 Decades (2002–2023). Clinical Infectious Diseases.
https://doi.org/10.1093/cid/ciaf407
- Domingo, P. et al. (2026). Author Correction: Dolutegravir restores gut microbiota in late-stage HIV-1 unlike darunavir: an open-label, randomized clinical trial. Nature Communications.
https://doi.org/10.1038/s41467-026-72458-w
- Elsevier. (n.d.). Scopus author details: Pere Domingo, Author ID 7102960369. Scopus.
https://www.scopus.com/pages/authors/7102960369